



## Drug and Device Law

Thursday, January 21, 2010

### Wajert-Bexis Published On FDA Shift Away From Internal Oversight

Proving they can do more than just blog, Dechert's two longest-running bloggers, Bexis and Sean Wajert (who writes the [Mass Tort Defense Blog](#)), along with associate Vince Gallo, recently wrote a "[Legal Backgrounder](#)" for the [Washington Legal Foundation](#) analyzing the FDA's decision to do away with the vetting of its Warning Letters by actual lawyers before such letters are issued.

The predictions: (1) more warning letters about less important things; (2) poorer quality and more mistakes as FDA employees apply their own subjective standards concerning what's a violation and what isn't; (3) increased liability risks as the folks on the other side of the "v." pick up on letters suffering from defects (1) and (2); and (4) a greater likelihood of warning letters that improperly curtail the First Amendment rights of regulated entities.

If that kind of stuff interests you, [take a look](#).

Posted by Beck, et al. at [7:30 AM](#) 

Labels: [FDA](#)

0 comments:

[Post a Comment](#)

[Newer Post](#)

[Home](#)

[Older Post](#)

Subscribe to: [Post Comments \(Atom\)](#)

### About

This blog contains [JIM BECK](#)'s personal views (and those of several other Dechert attorneys) of various topics that arise in the defense of pharmaceutical and medical device product liability litigation. Please read the [DISCLAIMER](#) about the nature of this blog, and understand that you are accepting its terms, before reading any of our posts.

### About Me

Beck, et al.

**MARK HERRMANN** Blogger Emeritus.

October 28, 2006 to December 16, 2009.

[JAMES M. BECK](#) is a Counsel resident in the Philadelphia office of Dechert LLP. He is the author of, among other things, *Drug and Medical Device Product Liability Handbook* (2004) (with Anthony Vale). He can be reached at [james.beck@dechert.com](mailto:james.beck@dechert.com).

[View my complete profile](#)

### Links

[Adam Smith, Esq.](#)

[American Law Institute](#)

[Eye on FDA](#)

[FDA](#)

[FDA Law Blog](#)

[Federal Judicial Center](#)

[Global Class Actions Clearinghouse](#)

[Judicial Panel on Multidistrict Litigation](#)

[Lawsuit Reform Watch](#)

[Life Sciences Legal Update](#)

[Mass Tort Defense](#)

[Medical Devices Today](#)

[National Center for State Courts](#)

[National Library of Medicine/NIH](#)

[New Jersey Mass Tort Information Center](#)

[Online Drug Encyclopedia](#)

[Pharma Business Review](#)

[Pharma Exec Blog](#)

[Pharmalot](#)

[Point of Law](#)

[Torts Prof](#)  
[Wall Street Journal Health Blog](#)  
[Wall Street Journal Law Blog](#)

---

[Index of Posts](#)

[Cross Jurisdictional Class Action Tolling Scorecard](#)

[Pre-Levine Drug Preemption Scorecard](#)

[Device Preemption Scorecard](#)

[New Drug/Vaccine Preemption Scorecard](#)

[No Injury Scorecard](#)

[Pioneer Defendant in Generic Drug Suit Scorecard](#)

---

## Archive

▼ 2010 (18)

▼ January (18)

[The Old One-Two On Appeal, Too \(and Two\)](#)

[No State-Law Market For "Fraud On The Market"](#)

[You say no injury. I say no standing Wajert-Bexis Published On FDA Shift Away From Inte...](#)

[Caveat Emptor](#)

[Fraud on the Market Takes It on the Chin in Pennsl...](#)

[There'll Always Be Posner \(again\)](#)

[Holiday Edition - Thanks](#)

[Once More Into The Breach](#)

[Beware The FDA Bearing Regulations: An Allergan U...](#)

[Third-Party Payer Actions Cannot Be Brought As Cla...](#)

[The Nuvaring Cycle, Revisited](#)

[FDCA Violations \(Still\) Not Privately Actionable](#)

[Negligence Per Se Does Not Equal "Parallel"](#)

[Gresham's Lawyers](#)

[Mopping it up](#)

[Baycol Class Action End Run Stuffed](#)

[There'll Always Be Posner](#)

▶ 2009 (362)

▶ 2008 (434)


▶ 2007 (278)

▶ 2006 (25)

---

## Subscribe To

 Posts

 Comments

---

## Topics

[Abigail Alliance](#) (3)  
[Accounting Standards](#) (4)  
[Accutane](#) (9)  
[Adverse Event Reporting](#) (6)  
[alabama](#) (1)  
[Alaska](#) (1)  
[ALI](#) (10)  
[Alternative Dispute Resolution](#) (1)  
[Amicus Curiae](#) (12)  
[Antitrust](#) (2)  
[Aredia/Zometa](#) (1)  
[Arkansas](#) (2)  
[Attorney-Client Privilege](#) (11)  
[Biomaterials](#) (1)  
[Black Box Warning](#) (2)  
[Blogging](#) (46)  
[Bystander](#) (1)  
[CAFA](#) (11)  
[California](#) (19)  
[Causation](#) (27)  
[CBE Regulation](#) (12)  
[Celebrex](#) (2)  
[Choice Of Law](#) (19)  
[Class Action](#) (90)  
[Clinical Trials](#) (9)  
[Colacicco](#) (30)  
[Collateral Estoppel](#) (4)  
[Comment K](#) (6)  
[Comparative Warnings](#) (1)  
[Compensable Injury](#) (5)  
[Compliance Defense](#) (3)  
[Component Parts](#) (1)  
[Confidentiality](#) (8)  
[Connecticut](#) (2)  
[Constitutional Law](#) (6)  
[Consumer Fraud](#) (42)  
[Conte](#) (11)  
[Cross-Examination](#) (1)  
[Cy Pres](#) (1)  
[Damages](#) (2)  
[Daubert](#) (29)  
[Delaware](#) (3)  
[Design Defect](#) (4)  
[Direct To Consumer Advertising](#) (1)  
[Discovery](#) (22)  
[Discovery Rule](#) (1)  
[Document Production](#) (3)  
[Duty To Test](#) (3)  
[E-Discovery](#) (5)  
[Economic Loss](#) (2)  
[Epidemiology](#) (9)  
[Erie Doctrine](#) (2)  
[Evidence](#) (18)  
[Expert Witness Opinion On Law](#) (6)  
[Expert Witnesses](#) (26)

[Express Preemption](#) (53)  
[Express Warranty](#) (5)  
[Extraterritoriality](#) (3)  
[False Claims Act](#) (6)  
[FDA](#) (32)  
[FDA Deference](#) (16)  
[FDA Evidence](#) (9)  
[FDA On Preemption](#) (19)  
[Fen-Phen](#) (2)  
[Field Preemption](#) (3)  
[First Amendment](#) (14)  
[Florida](#) (3)  
[Food](#) (7)  
[Foreign Regulations](#) (4)  
[Foreseeability](#) (1)  
[Forum Non Conveniens](#) (3)  
[Fosamax](#) (4)  
[Fraud](#) (6)  
[Fraud On The FDA](#) (18)  
[Fraudulent Joinder](#) (3)  
[Fraudulent Misjoinder](#) (1)  
[Generic Drugs](#) (18)  
[Georgia](#) (1)  
[Government Contingent Fee Contracts](#) (7)  
[Government Cost Recovery](#) (1)  
[Gunvalson](#) (6)  
[Heeding Presumption](#) (8)  
[HIPAA](#) (3)  
[HRT](#) (6)  
[Illinois](#) (4)  
[Implied Preemption](#) (63)  
[Implied Warranty](#) (3)  
[In-House Counsel](#) (2)  
[Indiana](#) (3)  
[Informed Consent](#) (7)  
[international](#) (14)  
[Interviewing Treating Physicians](#) (5)  
[Investigational Device](#) (4)  
[Investigational Drug](#) (6)  
[Iqbal](#) (14)  
[Jurisprudence](#) (26)  
[Kent](#) (15)  
[Kentucky](#) (1)  
[Labor Law](#) (2)  
[Law Review Articles](#) (43)  
[Learned Intermediary](#) (35)  
[Legal Writing](#) (3)  
[Legislation](#) (29)  
[Levine](#) (58)  
[Lists](#) (7)  
[Lone Pine Order](#) (2)  
[Manufacturer's Representatives](#) (3)  
[Manufacturing Defect](#) (2)  
[Marketing](#) (2)  
[Maryland](#) (1)  
[Mass Torts](#) (36)  
[Massachusetts](#) (1)  
[MDL](#) (73)

[Medical Device](#) (49)  
[Medical Monitoring](#) (18)  
[Medicare](#) (3)  
[Minnesota](#) (8)  
[Misjoinder](#) (4)  
[Mississippi](#) (3)  
[Missouri](#) (3)  
[Misuse](#) (3)  
[Motion In Limine](#) (2)  
[Negligence Per Se](#) (12)  
[Neurontin](#) (3)  
[Nevada](#) (1)  
[New Jersey](#) (17)  
[New Mexico](#) (1)  
[New York](#) (6)  
[North Carolina](#) (1)  
[Nuisance](#) (8)  
[Nuvaring](#) (6)  
[Off-Label Use](#) (35)  
[Ohio](#) (6)  
[Oklahoma](#) (2)  
[Oregon](#) (1)  
[Over The Counter Drugs](#) (1)  
[Parallel Violation Claims](#) (19)  
[Pennsylvania](#) (13)  
[Pleading](#) (42)  
[Practice Of Law](#) (10)  
[Preemption](#) (100)  
[Presumption Against Preemption](#) (8)  
[Principles Of Aggregate Litigation](#) (9)  
[Private Right Of Action](#) (15)  
[Product Identification](#) (7)  
[Puerto Rico](#) (1)  
[Punitive Damages](#) (19)  
[Recall](#) (2)  
[Reliance](#) (1)  
[Removal](#) (32)  
[Res Ipsa Loquitur](#) (1)  
[Rhode Island](#) (2)  
[RICO](#) (6)  
[Riegel](#) (32)  
[Safe Harbor](#) (6)  
[Sanctions](#) (1)  
[Science](#) (9)  
[Scorecards](#) (8)  
[Securities Law](#) (2)  
[Seroquel](#) (8)  
[Settlement](#) (11)  
[South Dakota](#) (1)  
[SSRIs](#) (19)  
[standing](#) (1)  
[State Of The Art](#) (3)  
[Statute Of Limitations](#) (7)  
[Statute Of Repose](#) (2)  
[Supreme Court](#) (25)  
[Taxation](#) (3)  
[Tennessee](#) (4)  
[Texas](#) (11)  
[Third-Party Payer](#) (10)

- [Tolling](#) (5)
- [Tort Reform](#) (7)
- [Translation Costs](#) (1)
- [Unavoidably Unsafe Product](#) (2)
- [Unjust Enrichment](#) (4)
- [Vaccine Act](#) (8)
- [Vaccines](#) (5)
- [Viagra](#) (1)
- [Vioxx](#) (28)
- [Voir Dire](#) (3)
- [Vytorin](#) (3)
- [Warning Adequacy](#) (9)
- [Warnings](#) (19)
- [Warranty](#) (4)
- [West Virginia](#) (3)
- [Wisconsin](#) (2)
- [Wyoming](#) (1)
- [Zyprexa](#) (22)

---

[ON TOPLIST.COM](#)



---

### Google Groups

Subscribe to Drug and Device Law (by email)

Email:

[Visit this group](#)

 [Subscribe in a reader](#)

[Follow us on Twitter](#)

---